Dorsey & Whitney Trust CO LLC Sells 584 Shares of Johnson & Johnson (NYSE:JNJ)

Dorsey & Whitney Trust CO LLC lowered its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.5% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 110,224 shares of the company’s stock after selling 584 shares during the period. Johnson & Johnson accounts for 1.2% of Dorsey & Whitney Trust CO LLC’s investment portfolio, making the stock its 16th biggest holding. Dorsey & Whitney Trust CO LLC’s holdings in Johnson & Johnson were worth $17,436,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also bought and sold shares of the company. Pathway Financial Advisors LLC boosted its position in Johnson & Johnson by 4.3% during the fourth quarter. Pathway Financial Advisors LLC now owns 5,438 shares of the company’s stock valued at $852,000 after buying an additional 226 shares during the period. Daiwa Securities Group Inc. boosted its position in Johnson & Johnson by 5.5% during the fourth quarter. Daiwa Securities Group Inc. now owns 297,850 shares of the company’s stock valued at $46,685,000 after buying an additional 15,490 shares during the period. OneAscent Financial Services LLC boosted its position in Johnson & Johnson by 82.8% during the fourth quarter. OneAscent Financial Services LLC now owns 9,838 shares of the company’s stock valued at $1,542,000 after buying an additional 4,457 shares during the period. Drive Wealth Management LLC boosted its position in Johnson & Johnson by 4.5% during the first quarter. Drive Wealth Management LLC now owns 9,625 shares of the company’s stock valued at $1,523,000 after buying an additional 414 shares during the period. Finally, Vestmark Advisory Solutions Inc. boosted its holdings in shares of Johnson & Johnson by 12.7% during the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock worth $3,070,000 after purchasing an additional 2,201 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Johnson & Johnson Stock Performance

NYSE:JNJ traded down $0.69 during midday trading on Friday, reaching $154.73. The stock had a trading volume of 7,393,260 shares, compared to its average volume of 7,332,051. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.17 and a quick ratio of 0.94. The stock has a market capitalization of $372.39 billion, a P/E ratio of 9.65, a PEG ratio of 2.76 and a beta of 0.52. The firm’s fifty day simple moving average is $148.36 and its 200-day simple moving average is $153.39. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $175.97.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 EPS for the quarter, topping the consensus estimate of $2.71 by $0.11. The company had revenue of $22.45 billion during the quarter, compared to analysts’ expectations of $22.33 billion. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.79%. Johnson & Johnson’s revenue was up 4.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.80 EPS. On average, equities research analysts forecast that Johnson & Johnson will post 10.02 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be given a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a dividend yield of 3.21%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s dividend payout ratio is presently 30.92%.

Analyst Ratings Changes

A number of brokerages have weighed in on JNJ. HSBC raised shares of Johnson & Johnson from a “hold” rating to a “buy” rating and raised their target price for the company from $169.00 to $170.00 in a research note on Thursday, April 18th. Bank of America cut their price target on shares of Johnson & Johnson from $180.00 to $170.00 and set a “neutral” rating on the stock in a report on Wednesday, April 17th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Sunday, June 30th. TD Securities cut their price target on shares of Johnson & Johnson from $195.00 to $185.00 in a report on Thursday. Finally, TD Cowen dropped their target price on shares of Johnson & Johnson from $195.00 to $185.00 and set a “buy” rating on the stock in a report on Thursday. Eight investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $175.00.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.